Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in AustraliaBusiness Wire • 07/30/24
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler ProductsBusiness Wire • 06/24/24
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in SpainBusiness Wire • 06/12/24
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE MeetingBusiness Wire • 05/20/24
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women's Wear Daily Beauty CEO SummitBusiness Wire • 05/15/24
Evolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the YearBusiness Wire • 05/10/24
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®Business Wire • 04/17/24
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceBusiness Wire • 03/26/24
Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028Seeking Alpha • 03/20/24
Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect?Zacks Investment Research • 03/13/24
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common StockBusiness Wire • 03/11/24
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 GuidanceBusiness Wire • 03/07/24